Who Generates More Revenue? Ionis Pharmaceuticals, Inc. or Supernus Pharmaceuticals, Inc.

Ionis vs. Supernus: A Decade of Revenue Rivalry

__timestampIonis Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 2014214161000122045000
Thursday, January 1, 2015283703000144427000
Friday, January 1, 2016346620000215003000
Sunday, January 1, 2017507666000302238000
Monday, January 1, 2018599674000408897000
Tuesday, January 1, 20191123000000392755000
Wednesday, January 1, 2020729000000520397000
Friday, January 1, 2021810000000579775000
Saturday, January 1, 2022587000000667238000
Sunday, January 1, 2023787647000607521000
Monday, January 1, 2024705138000
Loading chart...

Cracking the code

Revenue Race: Ionis vs. Supernus

In the competitive landscape of pharmaceuticals, revenue generation is a key indicator of success. Over the past decade, Ionis Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have been vying for dominance. From 2014 to 2023, Ionis consistently outperformed Supernus, with a peak revenue in 2019 that was nearly double that of Supernus. However, the gap has been narrowing. By 2022, Supernus achieved a revenue of approximately 667 million, surpassing Ionis for the first time. This shift highlights Supernus's strategic growth, marking a 447% increase from its 2014 revenue. Meanwhile, Ionis's revenue trajectory shows fluctuations, with a notable dip in 2022. As we look to the future, the question remains: will Supernus maintain its momentum, or will Ionis reclaim its lead? This dynamic rivalry underscores the ever-evolving nature of the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025